Stockscreener 앱 받기
7.1727
1.88%
-0.1273
전일 마감가:
$7.30
열려 있는:
$7.3
하루 거래량:
48,989
Relative Volume:
0.03
시가총액:
$1.51B
수익:
$331.41M
순이익/손실:
$-226.54M
주가수익비율:
-5.7382
EPS:
-1.25
순현금흐름:
$-97.31M
1주 성능:
-3.86%
1개월 성능:
-4.76%
6개월 성능:
+11.56%
1년 성능:
+40.44%
1일 변동 폭
$7.14
$7.31
1주일 범위
$6.92
$7.52
52주 변동 폭
$4.03
$8.88
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BCRX | 7.17 | 1.51B | 331.41M | -226.54M | -97.31M | -1.25 |
| VRTX | 447.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Hereditary Angioedema Therapeutics Market Report Outlines - openPR
Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com
BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highli - GuruFocus.com
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth By Investing.com - Investing.com Australia
BioCryst: Q3 Earnings Snapshot - Darien Times
BioCryst shares hold Buy rating, BofA sees entry point By Investing.com - Investing.com Canada
Piper Sandler lifts BioCryst Pharma target to $21 on Q3 beat - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - AOL
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Re - GuruFocus.com
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
BioCryst Pharmaceuticals Q3 2024 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC - MarketBeat
‘Breakthrough’ quarter for Island Pharmaceuticals - The Mercury
Island Pharmaceuticals enjoys big quarter - Courier Mail
Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday - MarketBeat
When (BCRX) Moves Investors should Listen - Stock Traders Daily
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - MSN
What's Going On With BioCryst Pharmaceuticals Stock? - MSN
BioCryst Presents New Real-World Evidence Showing High - GlobeNewswire
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - StockTitan
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):